MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
scientific article published on 07 February 2019
Author/s
author: Claudine Isaacs, Laura Esserman, Richard Schwab, Hope Rugo, Michelle E Melisko, Judy Boughey, Angela DeMichele, Douglas Yee, Donald H Berry, Kathy S. Albain, Meredith B Buxton, Amy Y Clark, Kirsten K Edmiston, Andres Forero-Torres, Nola M Hylton, Henry J. Kaplan, Larissa A Korde, Rita Nanda, Melissa Paoloni, Jane Perlmutter, William Symmans, Debasish Tripathy, Rebecca K Viscusi, Christina Yau, Teresa Helsten, Erica Stringer-Reasor, Erin M Ellis, Nora Jaskowiak, Kathleen Kemmer, Donald W Northfelt, Laura J. van't Veer, Garry D. Peterson, Julia L Clennell, Scott Berry, Katherine Steeg, Ruby Singhrao, Gillian L Hirst, Smita Asare, Amy Jo Chien
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.